Previous close | 8.47 |
Open | 8.47 |
Bid | 7.85 |
Ask | 8.05 |
Strike | 75.00 |
Expiry date | 2025-01-17 |
Day's range | 8.47 - 8.47 |
Contract range | N/A |
Volume | |
Open interest | 347 |
In this article, we will be taking a look at the 20 countries with the highest cancer survival rates in the world. If you do not want to learn about the cancer treatment in the US, head straight to the 5 Countries with the Highest Cancer Survival Rates in the World. Navigating the Terrain: The […]
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).